ArticleTrials2022
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.
Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
Efecto de Una intervención Multidisciplinaria de Estilo de Vida Sobre el Exposoma de Pacientes premenopáusicas Con cáncer de Mama Estadios I-III.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Serum lipidomic profiles associated with Mediterranean diet in overweight and obese breast cancer survivors: an exploratory study.European journal of nutrition · 2026Observational
- Digital Nutritional Care in Oncology: Opportunities to Enhance Quality of Life and Support Patient-Centered Care.Cancers · 2026Review
- The long road after breast cancer: survivorship issues and long-term treatment effects in young women.Frontiers in oncology · 2026Review
- Nutrition and Exercise Knowledge, Attitude, and Practice: A Scoping Review of Assessment Questionnaires in Cancer Survivorship.Nutrients · 2025Article
- Identifying relevant factors influencing cancer-related fatigue in patients with diffuse large B-cell lymphoma during chemotherapy.World journal of psychiatry · 2024Article
- Article
- FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer.Molecular cancer research : MCR · 2024Article
- Metabolic underpinnings of cancer-related fatigue.American journal of physiology. Endocrinology and metabolism · 2024Review
- Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis.Cancer pathogenesis and therapy · 2023Review
- A review of the impact of energy balance on triple-negative breast cancer.Journal of the National Cancer Institute. Monographs · 2023Review
- Article
- Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Underestimated Needs for Lymphoma Patients: An Assessment Issue.Acta bio-medica : Atenei Parmensis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 12 institutions in 2 countries.
Funding
Abstract
backgroundElevated body mass index (BMI) represents a risk factor for cancer-related fatigue (CRF). Weight loss interventions are feasible and safe in cancer survivors, leading to improved cardio-metabolic and quality of life (QOL) outcomes and modulating inflammatory biomarkers. Randomized data are lacking showing that a lifestyle intervention aimed at weight loss, combining improved diet, exercise, and motivational counseling, reduces CRF. Motivating to Exercise and Diet, and Educating to healthy behaviors After breast cancer (MEDEA) is a multi-center, randomized controlled trial evaluating the impact of weight loss on CRF in overweight or obese survivors of breast cancer. Herein, we described the MEDEA methodology.
methodsPatients (N = 220) with stage I-III breast cancer and BMI ≥ 25 kg/m DISCUSSION: MEDEA will test the impact of a weight loss intervention on CRF among overweight or obese BC survivors, potentially providing additional management strategies and contributing to establish weight loss support as a new standard of clinical care.
trial registrationClinicalTrials.gov NCT04304924.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.